PaySign Q1 2026 Earnings Highlight Robust Growth and Strategic Expansion in Patient Affordability and Plasma Businesses
PaySign’s Q1 2026 earnings show 50.8% revenue growth, operational leverage, and strategic expansion in pharmaceutical patient affordability and plasma businesses.